From pharmacogenomics to integrated personal omics profiling: A gap in implementation into healthcare

Personalized Medicine

Volumn 11, Issue 7, 2014, Pages 625-629

  Carlberg, Carsten ^a   Raunio, Hannu ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

education; epigenome; guidelines; GWAS; high throughput technologies; integrated personal omics profiling; personalized medicine; pharmacogenomics

Indexed keywords

HEALTH CARE; NOTE; PHARMACOGENOMICS;

EID: 84909972182     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.14.38     Document Type: Note

References (31)

1. Wang L, Mcleod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011).
2. Topol EJ. Individualized medicine from prewomb to tomb. Cell 157, 241-253 (2014).
3. Chen R, Mias GI, Li-Pook-Than J Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148, 1293-1307 (2012).
4. National Human Genome Research Institute, NIH. A catalog of published genome-wide association studies. www.genome.gov/gwastudies.
5. Welter D, MacArthur J, Morales J The NHGRI GWAS catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001-D1006 (2014).
6. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat. Biotechnol. 30, 1117-1124 (2012).
7. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141 (2013).
8. Sorich MJ, Polasek TM, Wiese MD. Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin. Pharmacol. Ther. 94, 376-382 (2013).
9. Lee MT, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J. Hum. Genet. 58, 334-338 (2013).
10. Turner RM, Pirmohamed M. Cardiovascular pharmacogenomics: expectations and practical benefits. Clin. Pharmacol. Ther. 95, 281-293 (2014).
11. US FDA. Table of pharmacogenomic biomarkers in drug labeling. www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
12. Cascorbi I, Tyndale R. Progress in pharmacogenomics: bridging the gap from research to practice. Clin. Pharmacol. Ther. 95, 231-235 (2014).
13. Carlberg C. The need for education in personalized medicine. Pers. Med. 9, 147-150 (2012).
14. The Cancer Genome Atlas. http://cancergenome.nih.gov.
15. Sanger Institute. Cancer Genome Project. www.sanger.ac.uk/research/projects/cancergenome.
16. Weng L, Zhang L, Peng Y, Huang RS. Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics 14, 315-324 (2013).
17. Downing NS, Ross JS. Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's personal genome service. JAMA 311, 793-794 (2014).
18. National Human Genome Research Institute, NIH. The ENCODE project: Encyclopedia of DNA Elements. www.genome.gov/encode.
19. NIH Roadmap Epigenomics Mapping Consortium. Roadmap Epigenomics Project. www.roadmapepigenomics.org.
20. Human Epigenome Project. www.epigenome.org.
21. Functional Annotation of the Mammalian Genome (FANTOM). http://fantom.gsc.riken.jp.
22. Deal RB, Henikoff S. Capturing the dynamic epigenome. Genome Biol. 11, 218 (2010).
23. Gibbs WW. Medicine gets up close and personal. Nature 506, 144-145 (2014).
24. Bouillon R, Van Schoor NM, Gielen E Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J. Clin. Endocrinol. Metab. 98, E1283-E1304 (2013).
25. Carlberg C, Seuter S, De Mello VD Primary vitamin D target genes allow a categorization of possible benefits of vitamin D3 supplementation. PLoS ONE 8, e71042 (2013).
26. Maliepaard M, Nofziger C, Papaluca M Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat. Rev. Drug Discov. 12, 103-115 (2013).
27. PharmGKB. www.pharmgkb.org.
28. GAPP Knowledge Base (GAPP KB). www.hugenavigator.net/GAPPKB/home.do.
29. Pharmacogenomics Research Network. www.pgrn.org.
30. Caudle KE, Klein TE, Hoffman JM Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug Metab. 15, 209-217 (2014).
31. Sorensen K, Brand H. Health literacy: the essential catalyst for the responsible and effective translation of genome-based information for the benefit of population health. Public Health Genomics 14, 195-200 (2011).